Strong Revenue Growth
Ypsomed reported sales of CHF 363 million in the first half year, with the core business growing by 21% from CHF 220 million to CHF 267 million.
Robust EBIT Margin
The company achieved an EBIT of CHF 152 million, with the Delivery Systems business showing an EBIT margin of 32.4%.
FDA Approval for Digital Device
Ypsomed received FDA approval for a digital device to support clinical trials, marking a significant innovation achievement.
Expansion Plans
Ypsomed is expanding its capacity to 1 billion devices by the end of the decade, with new facilities in China, Germany, and the U.S.
Sustainable Device Innovation
Ypsomed launched new platforms YpsoDot, YpsoFlow, and YpsoLoop, focusing on recyclable and sustainable devices.